Chugai Pharmaceutical Co. and F. Hoffmann-La Roche Ltd. announced Monday that they will enter a strategic tieup that will place the Japanese drug maker under the umbrella of its Swiss partner but retain the Chugai name.

The deal will enable the Roche group to establish a strong base for the development and sale of new products in Japan while helping Chugai engage in global research and development operations, they said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.